Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Malcy, Columbus & Reabold presentations - Video Webcast Here

EXCLUSIVE: Leo Koot, Exec Chairman, Columbus Energy speaks at London South East's Oil & Gas event
EXCLUSIVE: Stephen Williams, Reabold Resources speaks at London South East's Oil & Gas event


Astrazeneca Share Chat (AZN)



Share Price: 5,589.00Bid: 5,591.00Ask: 5,593.00Change: 0.00 (0.00%)No Movement on Astrazeneca
Spread: 2.00Spread as %: 0.04%Open: 5,613.00High: 5,642.00Low: 5,540.00Yesterday’s Close: 5,589.00


Share Discussion for Astrazeneca


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

quelfromage1
Posts: 489
Opinion:No Opinion
Price:5,606.00
RE: 55 quid
Wed 23:50
56 quid now, not just drugs, amphetamines!
 
Grayling
Posts: 1,309
Opinion:Hold
Price:5,626.00
AZN and Brexit
Wed 10:04
I hear AZN is "stockpiling" drugs in advance of a possible Brexit shambles. As they are Anglo-Swedish is it not possible that they could simply do a Unilever and re-domicile in Sweden? Thus they would sidestep the mess. It would be terrible result for the British economy particularly given the efforts taken by the UK government to prevent the sale of AZN to Pfizer a few years ago, but it would protect shareholder value.
Mylovelyhorse
Posts: 88
Opinion:No Opinion
Price:5,508.00
55 quid
13 Jul '18
Astrazeneca's on drugs ffs.
easyp
Posts: 1,054
Opinion:No Opinion
Price:5,181.00
RE: Exc news today and SP lousy!
4 Jul '18
No longer invested but remain a watcher and broadly agree with your summing up. For me if the sp fell to £50 I would buy a few but currently some small bio techs offer more share price growth/risk.
oldabutnowisa
Posts: 871
Opinion:Buy
Price:5,182.00
Exc news today and SP lousy!
2 Jul '18
Getting close to range where a top up could be tempting. If they drop below 51.00 a possible failure with MYSTIC late this year is almost discounted. The progress of the new drugs is also in for not a lot. It is all about covering the divi. That, IMHO, is what is holding the SP back. Also fear of Trump's attitude to big pharma. But AZN profit coming from whole world, especially Asia.
Grayling
Posts: 1,309
Opinion:Hold
Price:5,342.00
Alzheimers trial failure
12 Jun '18
Great shame that this did not meet expectations, but just underlines the complexity and difficulty of researching and treating this debilitating condition. Still there was no expected financial upside priced in and final year guidance remains unchanged. Let's hope that work continues quietly in the background towards a therapeutic angle for AD.
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:5,478.00
chcscoop11
26 May '18
Agreed but SP close to obvious resistance point. Jump over the 55.00 and we're in new high ground.
chcscoop11
Posts: 19
Opinion:No Opinion
Price:5,436.00
RE: Imfiinzi RNS today is MASSIVE
25 May '18
I hope you're right but c.20bps SP increase seems a bit muted for such great news
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:5,428.00
Imfiinzi RNS today is MASSIVE
25 May '18
This has repercussions I believe for the MYSTIC trials results to be announced December. If I am correct and those results too are positive, AZN go into orbit. Don't rely on my interpretation. DYOR please but I see �75 as realistic for Xmas in that event. Also great for all our chances of beating lung cancer!!!
Rhambo
Posts: 2,040
Opinion:No Opinion
Price:5,417.00
RE: Happening
21 May '18
fully loaded on pharma atm.... azn....hik....shp.... ripe for US pickings.
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:5,417.00
Happening
21 May '18
Hello hello! Price reacting rather nicely here. Wonder whether another big pharma is sniffing, scared they really might have a game changer drug worth more too much to leave alone.
easyp
Posts: 1,054
Opinion:No Opinion
Price:5,345.00
Interesting
18 May '18
http://www.lse.co.uk/sharecast-news-article.asp?ArticleCode=27483114&ArticleHeadline=Friday_preview_All_attention_on_AstraZeneca_and_Hikma_numbers

Remain a watcher but not invested. My money has gone further with OXB this year but remain a fan of the AZN dividend and possibilities.
easyp
Posts: 1,054
Opinion:No Opinion
Price:5,279.00
Trump
12 May '18
http://www.lse.co.uk/AllNews.asp?code=eshpe91j&headline=US_President_Trump_Provides_Outline_Of_Plan_To_Reduce_Drug_Prices

Took the dividend and sold due to other commitments and some concerns about Trump.
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:5,205.00
Q1 Results 18th May
7 May '18
Very interested to see if progress made end of last year in turning this big ship around in terms of profits actually continues and gets stronger end of Q1. Would have the brokers back of fag packet calcs leading to mark-up in SP.
daveycaferacer
Posts: 3,876
Opinion:Strong Buy
Price:4,985.50
Good news for HCM
19 Apr '18
This is great news for HCM who have developed Savolitinib in partnership with AZN and where Savolitinib is just about to commence a Phase 3 study as a combination therapy with Tagrisso - poss BT designation too
easyp
Posts: 1,054
Opinion:No Opinion
Price:4,972.00
RE: News
19 Apr '18
Good news today, barely a blip in the sp. Good dividend but sp ride a bit disappointing this year, thus far.
easyp
Posts: 1,054
Opinion:No Opinion
Price:4,990.50
RE: News
7 Apr '18
I am a bit wary of the markets in general right now so sold my AZN shares after the dividend payment but would buy back in if the trials proved encouraging.
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:4,990.50
RE: News
7 Apr '18
Saw that but still comforted that AZN persevering when they could have shut MYSTIC down early. Present price all but prices in total failure with MYSTIC anyway. And as I have said here many times, if it succeeds, will rise beyond 70!
easyp
Posts: 1,054
Opinion:No Opinion
Price:4,990.50
News
7 Apr '18
Melanoma trial failure deals heavy blow to immunotherapy hopes - https://www.ft.com/content/eb9e5ca0-39a5-11e8-8b98-2f31af407cc8 via @FT
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:4,860.00
More good news RNS
3 Apr '18
and SP falls!!
O K its a bad market but mark my words; when this one rerates you wont want to be short of them.
easyp
Posts: 1,054
Opinion:Hold
Price:4,889.50
RE: Annual Report
19 Mar '18
On the basis of what we do know the sp looks cheap imo.
oldabutnowisa
Posts: 871
Opinion:No Opinion
Price:4,867.00
Annual Report
17 Mar '18
crashed through letter-box today. Worth a browse. Says the big boat is starting to turn around and make its profits from the new mix of drugs. May be true but will need more time - at least another two years IMO. Happy bed-time reading!
easyp
Posts: 1,054
Opinion:Hold
Price:4,799.00
RE: Todays RNS is HUGE
15 Mar '18
Maybe, possibly not as there might be bad news pending about the trial none the less we are days away from a good dividend payout and there are other products in the pipeline.

In my opinion the current sp well under what the company is really worth but the markets do not see it that way. It could be partly down to Brexit uncertainty but not much.
oldabutnowisa
Posts: 871
Opinion:Strong Buy
Price:4,800.00
Todays RNS is HUGE
12 Mar '18
MYSTIC final result put back from 1st half this year to 2nd half. I feel positive about this because if the big immunotherapy test was going badly adverse, why drag it out? So while it would be nice to have it early, the most important thing by a country mile is that it has been PROVED effective. I can wait a bit longer for that!




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.